Please login to the form below

Not currently logged in

AZ’s Sean Bohen to exit after business overhaul; report

AstraZenecaRecent departures raises concern among analysts

GSK upbeat on its return to oncology market

ZejulaZejula signals comeback after four year hiatus

Nektar confirms BMS deal for NKTR-214 is on track

Shares in Nektar rose 10% in the wake of the presentation at JPM healthcare conference

Lilly adds to pharma M&A run with $8bn Loxo buy-out

Eli Lilly HQLilly claims company ahead of more dominant oncology players

Sanofi and Regeneron re-jig immuno-oncology deal

Sanofi receptionPartners refocus around two promising bispecific candidates

Drug pricing is pharma’s top concern in 2019

More than half of industry respondents say pricing will have the greatest negative impact this year

After December slump, what’s in store for biotech in 2019?

Analysts say 2019 could be a "big year for proceeds if not for deal count"

Blow for J&J as court refuses to overturn talc verdict

Reuters and company at loggerheads over veracity of claims

Business in the USAHealth coverage across state lines

Despite a total lack of legislative wins, the new administration has made its presence felt at home and abroad

  • Ho_Ung_KimStanding out in a crowd

    Celltrion Healthcare’s Ho-Ung Kim on pricing, market access and regulatory challenges for successfully developing biosimilars

  • HeadsThe diseased organisation

    Like humans, organisations can be afflicted by genetic disorders that hinder performance and threaten survival but these can be understood and cured

Featured jobs

Subscribe to our email news alerts


Add my company
Complete HealthVizion

Complete HealthVizion is a global team of fresh thinkers who aspire to be better every day. We create life-changing medical...

Latest intelligence

NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...